Thank you for sharing those. I'm reading quickly and don't have any medical expertise, but it seems that they're calling for more research because intermittent ADT *might* be useful for advanced/metastatic prostate cancer, but not actually recommending it (yet) because there's not sufficient evidence to support it.

The first one still recommends that "Based on randomized studies, continuous ADT appears appropriate for patients with advanced, metastatic prostate cancer" and the second says that "patients with large tumors, multiple metastases, and prostate-specific antigen (PSA) levels >100 ng/mL do not have a good prognosis with IADT, mainly due to a shorter life expectancy and a shorter off-treatment period" (for now, anyway).

For people with non-metastatic prostate cancer, the second one (IIRC) points out that intermittent ADT has a slightly-higher mortality rate from cancer, but that's balanced by a slightly-lower mortality rate from other causes like heart disease associated with the side-effects of ADT.

I hope that with more research, we'll find a way to reduce or limit ADT use for people with metastatic or oligometastatic prostate cancer, but for now, it looks like we're not quiet there yet.